US Underuse of GLP-1RA, SGLT-2i in Type 2 Diabetes Persists
A large, US study found that just 1 in 8 patients with type 2 diabetes received first-line medications for comorbid atherosclerotic cardiovascular disease, heart failure, and diabetic nephropathy. First Look